申请人:RESPIVERT LIMITED
公开号:US20150225427A1
公开(公告)日:2015-08-13
There are provided compounds of formula I, (I):
wherein R
1
to R
5
, X
1
, X
2
, Ar, L, E, A, A1, G and G
1
have meanings given in the description, which compounds have anti-inflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
提供了公式I的化合物,其中R1至R5,X1,X2,Ar,L,E,A,A1,G和G1的含义在说明中给出,这些化合物具有抗炎活性(例如,通过抑制:p38丝裂原活化蛋白激酶酶家族中的一个或多个成员;Syk激酶;和酪氨酸激酶Src家族的成员之一),并且可用于治疗,包括在制药组合中,特别是用于治疗炎症性疾病,包括肺部、眼部和肠道的炎症性疾病。